Windjammer Capital has announced it has acquired Bio X Cell (BXC).
BXC, founded in 1997 and based in Lebanon, N.H., is a producer of monoclonal antibodies for use in both in vivo and in vitro pre-clinical research applications.
Windjammer, based in Newport Beach, Calif., and Waltham, Mass., is a private equity firm focused